Since overexpression of GSK-3β renders HCC resistant to certain chemotherapies like retinoid and sorafenib, the therapeutic significance of targeting GSK-3β may lie on its combination with other anticancer drugs. Here, GSK3B is linked to hepatocellular carcinoma.